Viking Therapeutics (NASDAQ:VKTX) is set to announce its earnings results after the market closes on Thursday, August 1st. Analysts expect the company to announce earnings of ($0.09) per share for the quarter.
Viking Therapeutics (NASDAQ:VKTX) last released its earnings results on Thursday, May 2nd. The biotechnology company reported ($0.07) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.02. On average, analysts expect Viking Therapeutics to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Viking Therapeutics stock traded up $0.23 during trading hours on Wednesday, hitting $7.86. 33,152 shares of the company traded hands, compared to its average volume of 1,105,100. The company has a market cap of $549.74 million, a price-to-earnings ratio of -19.81 and a beta of 2.31. The firm’s 50-day moving average price is $8.12. Viking Therapeutics has a 1-year low of $6.97 and a 1-year high of $24.00.
Several equities analysts have commented on VKTX shares. BidaskClub cut shares of Extraction Oil & Gas from a “hold” rating to a “sell” rating in a research note on Saturday, May 4th. ValuEngine cut shares of Zuora from a “buy” rating to a “hold” rating in a research note on Saturday, June 1st. Oppenheimer started coverage on shares of Neurocrine Biosciences in a research note on Tuesday, July 16th. They set an “outperform” rating and a $100.00 target price on the stock. Stifel Nicolaus initiated coverage on shares of GENFIT S A/ADR in a research note on Tuesday, June 25th. They set a “hold” rating on the stock. Finally, CIBC lowered their price objective on shares of Stuart Olson from C$5.00 to C$4.00 in a research note on Tuesday, July 16th. One research analyst has rated the stock with a sell rating, one has given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. Viking Therapeutics presently has an average rating of “Buy” and a consensus target price of $20.53.
Viking Therapeutics Company Profile
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase II clinical trials to treat patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol.
Featured Story: Quiet Period
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.